Day: April 18, 2024

  April 18, 2024 RCI Banque: ‘’2023 Annual Report is now available’’ The RCI Banque group ‘’2023 Annual Report’’ is now available on the Mobilize Financial Services website www.mobilize-fs.com      AttachmentPress Release – Mise à dispo Annual report 2023

April 18, 2024 RCI Banque: ‘’2023 Annual Report’’ The RCI Banque group ‘’2023 Annual Report’’ is now available on the Mobilize Financial Services website www.mobilize-fs.comAttachmentRCI_MOBILIZE_2023_RA_MEL_EN

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,000,000 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant. The warrants have an exercise price of $0.80 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds from the offering,...

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants to purchase up to 375,000 shares of common stock at an exercise price of $3.10 per share. The unregistered warrants to be issued in the private placement will become...

MELBOURNE, Australia, April 19, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at a purchase price of $2.00 per ADS. In addition, in a concurrent private placement, the Company will issue unregistered warrants (“Warrants”) to purchase up to 1,000,000 ADSs. The Warrants will have an exercise price of $2.00 per ADS, will be exercisable...

Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of DirectorsIncrease in the dividend from CHF 2.90 to CHF 3.00 per share Monica Manotas elected as additional independent member of the Board of Directors Lukas Braunschweiler, Myra Eskes, Oliver Fetzer, Matthias Gillner, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of Directors Lukas Braunschweiler confirmed by shareholders as Chair of the Board Myra Eskes, Oliver Fetzer, Christa Kreuzburg and Daniel R. Marshak confirmed as members of the Compensation Committee Various amendments to the Articles of Incorporation approved All proposals relating to compensation approved Approval of the Report on Non-Financial Matters 2023 (Sustainability Report)Männedorf, Switzerland, April 18, 2024 – The Annual...